BLAINJECTIONINJECTABLE
Approved
Mar 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
ILUMYA (tildrakizumab-asmn) by Sun Pharmaceutical Industries Limited is interleukin-23 antagonists [moa]. First approved in 2018.
Drug data last refreshed 18h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ILUMYA (tildrakizumab-asmn) is a monoclonal antibody that selectively antagonizes interleukin-23 (IL-23), a key cytokine driver of inflammatory skin diseases. It is administered via subcutaneous injection and is indicated for patients with moderate-to-severe plaque psoriasis. The drug works by blocking IL-23 signaling, reducing the inflammatory cascade responsible for psoriatic plaques.
$32MPart D
PeakProduct is at peak lifecycle with modest Medicare utilization (1,822 claims in 2023), suggesting a stable but non-dominant market position within the IL-23 antagonist class.
Mechanism of Action
Interleukin-23 Antagonists
Pharmacologic Class:
Interleukin-23 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ILUMYA is a mature, peak-stage biologic with modest but stable market penetration in psoriasis. Careers on this product focus on defending market share against competitive IL-23 antagonists and managing payer relationships in a competitive landscape. Strategic emphasis is on differentiation, patient persistence, and preparing for eventual biosimilar competition.
Brand Manager
Worked on ILUMYA at Sun Pharmaceutical Industries Limited? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.